Inhibitory effect of F-1322 on allergic eosinophil infiltration in airways

European Journal of Pharmacology

Volumn 343, Issue 2-3, 1998, Pages 233-237

  Mochizuki, Akinori ^a   Lee, Bunsho ^a   Shibata, Masahiro ^a   Kasai, Masaaki ^b   Tanaka, Tooru ^b   Iwamoto, Itsuo ^b  

^a FUJIREBIO INC   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Eosinophil migration; F 1322; Interleukin 5 production

Indexed keywords

ANTIALLERGIC AGENT; ANTIGEN; DEXAMETHASONE; F 1322; INTERLEUKIN 5; LEUKOTRIENE B4; RECOMBINANT INTERLEUKIN 5; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

AIRWAY; ALLERGIC DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION; LUNG LAVAGE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SENSITIZATION; TRACHEA;

ANIMALS; ANTI-ASTHMATIC AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL MOVEMENT; EOSINOPHILS; FEMALE; GUINEA PIGS; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-5; MICE; MICE, INBRED BALB C; NAPHTHALENES; TRACHEA;

EID: 0032545915     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01534-3     Document Type: Article

References (16)

1. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146:1991;108-113.
2. Coëffier E., Joseph D., Vargaftig B.B. Activation of guinea-pig eosinophils by human recombinant IL-5: Selective priming to platelet-activating factor-acether and interference of its antagonists. J. Immunol. 147:1991;2595-2602.
3. Frigas E., Gleich G.J. The eosinophil and the pathophysiology of asthma. J. Allergy Clin. Immunol. 77:1986;527-537.
4. Gibson P.G., Dolovich J., Ramsdale E.H., Hargreave F.E. Chronic cough: Eosinophilic bronchitis without asthma. Lancet. i:1989;1346-1348.
5. Hansel T.T., Pound J.D., Pilling D., Kitas G.D., Salmon M., Gentle T.A., Lee S.S., Thompson R.A. Purification of human blood eosinophils by negative selection using immunomagnetic beads. J. Immunol. Methods. 122:1989;97-103.
6. Holgate S.T., Beasley R., Twentyman O.P. The pathogenesis and significance of bronchial hyperresponsiveness in airways disease. Clin. Sci. 73:1987;561-572.
7. Horn B.R., Robin E.D., Theodore J., Van Kessel A. Total eosinophil counts in the management of bronchial asthma. New Engl. J. Med. 292:1975;1152-1155.
8. Itoh K., Mukaiyama O., Satoh Y., Yamaguchi T., Iizuka Y. Effect of CS-518, a thromboxane synthetase inhibitor, on eosinophil function. Eur. J. Pharmacol. 239:1993;159-169.
9. Kaneko T., Alvarez R., Ueki I.F., Nadel J.A. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell. Signal. 7:1995;527-534.
10. Kay A.B. Studies on eosinophil leukocyte migration II. Factors specifically chemotactic for eosinophils and neutrophils generated from guinea-pig serum by antigen-antibody complexes. Clin. Exp. Immunol. 7:1970;723-737.
11. Lee B., Takasaki K., Mochizuki A., Tamura N., Higashide Y., Yamaura T. Pharmacological profiles of F-1322, a novel anti-asthmatic agent. (1) Mechanisms of action. Folia Pharmacol. Jpn. 106:1995;31-40. abstract in English.
12. Muñoz N.M., Douglas I., Mayer D., Herrnreiter A., Zhu X., Leff A.R. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am. J. Resp. Crit. Care Med. 155:1997;1398-1403.
13. + T-lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea. Am. Rev. Respir. Dis. 146:1992;374-377.
14. Ochiai K., Iwamoto I., Takahashi H., Yoshida S., Nakagawa H., Tomioka H., Yoshida S. Characteristic of an anti-eosinophil monoclonal antibody that recognizes granulocytes from patients with blood eosinophilia but not from subjects without eosinophilia. Clin. Exp. Immunol. 84:1991;283-288.
15. Yamaguchi Y., Suda T., Suda J., Eguchi M., Miura Y., Harada N., Tominaga A., Takatsu K. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J. Exp. Med. 167:1988;43-56.
16. Yamaguchi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., Torisu M., Mita S., Tominaga A., Takatsu K., Suda T. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival: IL-5 is an eosinophil chemotactic factor. J. Exp. Med. 167:1988;1737-1742.